Trial · NCT04562090
Results by group39
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 39
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg Group | Mirabegron 50 mg | -3.76 | Standard Deviation 0.40 | micturitions per 24 hours | |
| Number of Participants With Treatment Emergent Adverse Events | Mirabegron 25 mg | 18 | participants | ||
| Number of Participants With Treatment Emergent Adverse Events | Mirabegron 50 mg | 58 | participants | ||
| Change From Baseline to Week 12 in Post Void Residual (PVR) Volume | Mirabegron 25 mg | -2.7 | Standard Deviation 26.3 | milliliter | |
| Change From Baseline to Week 12 in Post Void Residual (PVR) Volume | Mirabegron 50 mg | -1.3 | Standard Deviation 24.5 | milliliter | |
| Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Mirabegron 25 mg | Change at Week 4 | -2.09 | Standard Deviation 2.35 | urgency episodes per 24 hours |
| Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Mirabegron 50 mg | Change at Week 4 | -2.53 | Standard Deviation 5.54 | urgency episodes per 24 hours |
| Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Mirabegron 25 mg | Change at Week 8 | -2.66 | Standard Deviation 2.57 | urgency episodes per 24 hours |
| Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Mirabegron 50 mg | Change at Week 8 | -2.98 | Standard Deviation 5.78 | urgency episodes per 24 hours |
| Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Mirabegron 25 mg | Change at Week 12 | -2.57 | Standard Deviation 1.92 | urgency episodes per 24 hours |
| Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Mirabegron 50 mg | Change at Week 12 | -3.55 | Standard Deviation 5.75 | urgency episodes per 24 hours |
| Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Mirabegron 25 mg | Change at Week 4 | -0.48 | Standard Deviation 1.82 | incontinence episodes per 24 hours |
| Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Mirabegron 50 mg | Change at Week 4 | -0.77 | Standard Deviation 2.47 | incontinence episodes per 24 hours |
| Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Mirabegron 25 mg | Change at Week 8 | -1.06 | Standard Deviation 1.85 | incontinence episodes per 24 hours |
| Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Mirabegron 50 mg | Change at Week 8 | -0.89 | Standard Deviation 2.59 | incontinence episodes per 24 hours |
| Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Mirabegron 25 mg | Change at Week 12 | -1.03 | Standard Deviation 1.77 | incontinence episodes per 24 hours |
| Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Mirabegron 50 mg | Change at Week 12 | -0.97 | Standard Deviation 2.63 | incontinence episodes per 24 hours |
| Change From Baseline in Mean Number of Nighttime Incontinence Episodes Per 24 Hours | Mirabegron 25 mg | Change at Week 4 | -0.37 | Standard Deviation 1.11 | incontinence episodes per 24 hours |
| Change From Baseline in Mean Number of Nighttime Incontinence Episodes Per 24 Hours | Mirabegron 50 mg | Change at Week 4 | -0.47 | Standard Deviation 3.06 | incontinence episodes per 24 hours |
| Change From Baseline in Mean Number of Nighttime Incontinence Episodes Per 24 Hours | Mirabegron 25 mg | Change at Week 8 | -0.67 | Standard Deviation 1.50 | incontinence episodes per 24 hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04562090/results